INCIDENCE OF CHEMOTHERAPY-INDUCED PERIPHERAL NEUROPATHY IN CANCER PATIENTS IN CLINICAL PRACTICE

Abstract

Chemotherapy-induced peripheral neuropathy (CIPN) is major neurologic toxic event, with a negative impact on patient's quality of life (QoL), and frequently requires dose modification or treatment discontinuation. The prevalence of CIPN is expecting to increase as cancer survival continue to improve. The study was conducted on 163 eligible patients with neurotoxic chemotherapy, from the Oncology Department of Clinical Emergency Hospital of Constana, Romania between January 2017 and June 2018. Patients received a taxane -paclitaxel or docetaxel, platinum-based agents -cisplatin, carboplatin or oxaliplatin, either as single agent or combination. The incidence of CIPN was 68.09%. The highest incidence of CIPN was associated with paclitaxel (73.14%), and with oxaliplatin (72.22%), followed by cisplatin (30%), and with docetaxel (23.07%). Cumulative dose, regimen schedule, and treatment duration are important risk factors for the development of chemotherapy-induced peripheral neuropathy. Advanced age does not seem to be a significant risk factor of CIPN in our analysis in patients without significant comorbidity.